AQR Arbitrage’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

AQR Arbitrage’s Portfolio DMAAR Stock Details DMAAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$37.2K	Hold	372,322	–	–	﹤0.01%	601
2026 Q1	$20.5K	Sell	372,322 -7,992	-2%	-$846	﹤0.01%	545
2025 Q4	$60.1K	Sell	380,314 -119,686	-24%	-$23.2K	﹤0.01%	461
2025 Q3	$109K	Hold	500,000	–	–	﹤0.01%	383
2025 Q2	$62.5K	Hold	500,000	–	–	﹤0.01%	351
2025 Q1	$65K	Buy	+500,000	New	+$70.2K	﹤0.01%	346

Other funds holding DMAAR

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

HCM

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

RCM

Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

AGM

Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return

AQR Arbitrage's DMAAR Position: Q2 2026 in Review

AQR Arbitrage held its Drugs Made In America Acquisition Corp Rights (DMAAR) position steady in Q2 2026 at 372,322 shares worth $37.2K. The position accounts for ﹤0.01% of the portfolio, ranked #601.

AQR Arbitrage first reported a position in DMAAR in Q1 2025 and has held it in 6 quarters since. The position peaked at $109K in Q3 2025. 28 funds tracked by Wall St. Rank hold DMAAR as of Q2 2026.

AQR Arbitrage held 372,322 shares of Drugs Made In America Acquisition Corp Rights worth $37.2K as of Q2 2026.
AQR Arbitrage left its Drugs Made In America Acquisition Corp Rights share count unchanged in Q2 2026.
Drugs Made In America Acquisition Corp Rights made up ﹤0.01% of AQR Arbitrage's portfolio in Q2 2026, its #601 holding.
AQR Arbitrage first reported a position in Drugs Made In America Acquisition Corp Rights in Q1 2025 and has held it in 6 quarters since.
AQR Arbitrage's Drugs Made In America Acquisition Corp Rights position peaked at $109K in Q3 2025.
28 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q2 2026.

Based on AQR Arbitrage's 13F filing for Q2 2026, filed 14 Aug 2026.